Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-17T18:45:19.273Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluating State-Specific Antibiotic Resistance Measures Derived from Central Line-Associated Bloodstream Infections, National Healthcare Safety Network, 2011

Published online by Cambridge University Press:  05 January 2015

Minn M. Soe ,
Jonathan R. Edwards ,
Dawn M. Sievert ,
Philip M. Ricks ,
Shelley S. Magill  and
Scott K. Fridkin
Minn M. Soe*
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, Georgia
Jonathan R. Edwards
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, Georgia
Dawn M. Sievert
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, Georgia
Philip M. Ricks
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, Georgia
Shelley S. Magill
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, Georgia
Scott K. Fridkin
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, Georgia
*
Address correspondence to Minn M. Soe, MD, MPH, MS A-24, CDC, 1600 Clifton Road, NE Atlanta, GA 30333 (msoe@cdc.gov).
Get access Rights & Permissions [Opens in a new window]

Abstract

DISCLOSURE

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Diseases Registry.

OBJECTIVE

Describe the impact of standardizing state-specific summary measures of antibiotic resistance that inform regional interventions to reduce transmission of resistant pathogens in healthcare settings.

DESIGN

Analysis of public health surveillance data.

METHODS

Central line–associated bloodstream infection (CLABSI) data from intensive care units (ICUs) of facilities reporting to the National Healthcare Safety Network in 2011 were analyzed. For CLABSI due to methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum cephalosporin (ESC)-nonsusceptible Klebsiella species, and carbapenem-nonsusceptible Klebsiella species, we computed 3 state-level summary measures of nonsusceptibility: crude percent nonsusceptible, model-based adjusted percent nonsusceptible, and crude infection incidence rate.

RESULTS

Overall, 1,791 facilities reported CLABSIs from ICU patients. Of 1,618 S. aureus CLABSIs with methicillin-susceptibility test results, 791 (48.9%) were due to MRSA. Of 756 Klebsiella CLABSIs with ESC-susceptibility test results, 209 (27.7%) were due to ESC-nonsusceptible Klebsiella, and among 661 Klebsiella CLABSI with carbapenem susceptibility test results, 70 (10.6%) were due to carbapenem-nonsusceptible Klebsiella. All 3 state-specific measures demonstrated variability in magnitude by state. Adjusted measures, with few exceptions, were not appreciably different from crude values for any phenotypes. When linking values of crude and adjusted percent nonsusceptible by state, a state’s absolute rank shifted slightly for MRSA in 5 instances and only once each for ESC-nonsusceptible and carbapenem-nonsusceptible Klebsiella species. Infection incidence measures correlated strongly with both percent nonsusceptibility measures.

CONCLUSIONS

Crude state-level summary measures, based on existing NHSN CLABSI data, may suffice to assess geographic variability in antibiotic resistance. As additional variables related to antibiotic resistance become available, risk-adjusted summary measures are preferable.

Infect Control Hosp Epidemiol 2015;36(1): 54–64

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 36 , Issue 1 , January 2015 , pp. 54 - 64
Copyright
© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.U.S. Department of health and Human Services & Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention website. http://www.cdc.gov/drugresistance/threat-report-2013/index.html. Published 2013. Accessed February 3, 2014.Google Scholar
2.Cosgrove, SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006;42(Suppl 2):S82–S89.Google Scholar
3.Maragakis, LL, Perencevich, EN, Cosgrove, SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008;6:751–763.Google Scholar
4.Shorr, AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009;37:1463–1469.CrossRefGoogle ScholarPubMed
5.European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2011. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: European Centre for Disease Control and Prvention, 2012.Google Scholar
6.Molton, JS, Tambyah, PA, Ang, BS, Ling, ML, Fisher, DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis 2013;56:1310–1318.Google ScholarPubMed
7.Master, RN, Deane, J, Opiela, C, Sahm, DF. Recent trends in resistance to cell envelope-active antibacterial agents among key bacterial pathogens. Ann N Y Acad Sci 2013;1277:1–7.Google Scholar
8.Stelling, JM, Travers, K, Jones, RN, Turner, PJ, O'Brien, TF, Levy, SB. Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Emerg Infect Dis 2005;11:873–882.CrossRefGoogle ScholarPubMed
9.Sannes, MR, Kuskowski, MA, Johnson, JR. Geographical distribution of antimicrobial resistance among Escherichia coli causing acute uncomplicated pyelonephritis in the United States. FEMS Immunol Med Microbiol 2004;42:213–218.Google Scholar
10.Zilberberg, MD, Shorr, AF, Kollef, MH. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000–2005. Emerg Infect Dis 2008;14:1756–1758.Google Scholar
11.Zhanel, GG, DeCorby, M, Adam, H, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother 2010;54:4684–4693.CrossRefGoogle ScholarPubMed
12.Kallen, AJ, Hidron, AI, Patel, J, Srinivasan, A. Multidrug resistance among Gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006–2008. Infect Control Hosp Epidemiol 2010;31:528–531.CrossRefGoogle Scholar
13.Gales, AC, Jones, RN, Sader, HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother 2011;66:2070–2074.CrossRefGoogle ScholarPubMed
14.Diekema, DJ, Pfaller, MA, Schmitz, FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001;32(Suppl 2):S114–S132.Google Scholar
15.Centers for Disease Control and Prevention. CDC vital signs. Making health care safer. Centers for Disease Control and Prevention website. http://www.cdc.gov/vitalsigns/pdf/2011-03-vitalsigns.pdf. Accessed April 2014.Google Scholar
16.Siegel., JD, Rhinehart., E, Jackson., M, Chiarello., L. Committee. tHICPA. Management of multidrug-resistant organisms in healthcare settings, 2006. Centers for Disease Control and Prevention website. http://www.cdc.gov/hicpac/pdf/MDRO/MDROGuideline2006.pdf. Published 2006. Accessed February 3, 2014.Google Scholar
17.Smith, DL, Dushoff, J, Perencevich, EN, Harris, AD, Levin, SA. Persistent colonization and the spread of antibiotic resistance in nosocomial pathogens: Resistance is a regional problem. Proc Soc Natl Acad Sci USA 2004;101:5696–5696.CrossRefGoogle ScholarPubMed
18.Schwaber, MJ, Lev, B, Israeli, A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli Hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52:848–855.CrossRefGoogle Scholar
19.Won, SY, Munoz-Price, LS, Lolans, K, et al. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2011;53:532–540.CrossRefGoogle ScholarPubMed
20.Wisconsin Division of Public Health. Guidance for preventing transmission of carbapenem-resistant Enterobacteriaceae (CRE) in acute care and long-term care hospitals. Wisconsin Division of Public Health website. http://www.dhs.wisconsin.gov/publications/P0/p00532A.pdf. Published 2014. Accessed February 3, 2014.Google Scholar
21.Centers for Disease Control and Prevention. National and state healthcare associated infections: Progress Report. Centers for Disease Control and Prevention website. http://www.cdc.gov/HAI/pdfs/progress-report/hai-progress-report.pdf. Published 2014. Accessed April 2014.Google Scholar
22.Council of state and territorial epidemiologists. Placing central line-associated bloodstream infections (CLABSI) under nationwide surveillance through the National Healthcare Safety Network (NHSN). http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PS/12-ID-06FINAL.pdf. Accessed August 2014.Google Scholar
23. Virginia department of health's healthcare-associated infections (HAI) program. SYNERGY: combining efforts for HAI prevention http://www.vdh.virginia.gov/Epidemiology/Surveillance/HAI/documents/pdf/VDH%20HAI%20NewsletterVol5Issue3FINAL.pdf. Accessed August 2014.Google Scholar
24.U.S. Government Accountability Office. Antibiotic Resistance: Data Gaps Will Remain Despite HHS Taking Steps to Improve Monitoring. GAO-11-406, 2011. Washington D.C. Government Accountability Office website. http://www.gao.gov/assets/320/319110.pdf. Published 2011. Accessed February 3, 2014.Google Scholar
25.Centers for Disease Control and Prevention. Operational guidance for acute care hospitals to report central line-associated bloodstream infection (CLABSI) data to CDC’s NHSN for the purpose of fulfilling CMS’s hospital inpatient quality reporting (IQR) Requirements. Centers for Disease Control and Prevention website. http://www.cdc.gov/nhsn/PDFs/HPS-manual/Operational-Guidance-HPS-Flu-Vaccination-Sum-Acute-Care.pdf. Published 2012. Accessed January 2014.Google Scholar
26.Rothman, KJ, Boice, JDJ. Epidemiologic analysis with a programmable calculator. NIH Pub No. 79-1649. Bethesda, MD: National Institutes of Health, 1979.Google Scholar
27.Graubard, BI, Korn, EL. Predictive margins with survey data. Biometrics 1999;55:652–659.Google Scholar
28.Wolter, KM. Introduction to Variance Estimation. 2nd ed. New York, NY: Springer, 2007.Google Scholar
29.Tillotson, GS, Draghi, DC, Sahm, DF, Tomfohrde, KM, del Fabro, T, Critchley, IA. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005–07: laboratory-based surveillance study. J Antimicrob Chemother 2008;62:109–115.Google Scholar
30.Hennekens, CH, Buring, JE, Mayrent, SL. Epidemiology in Medicine. Boston, MA: Little, Brown and Co, 1987.Google Scholar
31.Kuster, SP, Ruef, C, Bollinger, AK, et al. Correlation between case mix index and antibiotic use in hospitals. J Antimicrob Chemother Oct 2008;62:837–842.CrossRefGoogle ScholarPubMed
32.Magill, SS, Edwards, JR, Bamberg, W, et al. Multi-state point prevalence survey and national burden of healthcare-associated infections. N Engl J Med 2014;370:1198–1208.Google Scholar
33.Schwaber, MJ, De-Medina, T, Carmeli, Y. Epidemiological interpretation of antibiotic resistance studies—what are we missing? Nature Rev Microbiol 2004;2:979–983.CrossRefGoogle ScholarPubMed